VLS Valneva SE

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Financial Report, the Company's Annual Management Report, the Board of Directors’ Corporate Governance Report and the Company’s Sustainability Statement. The Sustainability Statement is available in both English and French.

These documents are available on Valneva’s website () and will also be available on the AMF () and SEC () websites, respectively. Hard copies of these documents may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first chikungunya vaccine, as well as certain third-party vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at .







Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine

VP, Global Communications and European Investor Relations

M +33 (0)6 4516 7099



















Joshua Drumm, Ph.D.

VP, Global Investor Relations

M 20













        		 

Attachment



EN
25/03/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Damien Choplain ... (+2)
  • Damien Choplain
  • Oscar Haffen Lamm
VLS VALNEVA SE

Valneva: resuming coverage

As of 30th July 2025, we resume coverage of Valneva, which will now be followed by Damien Choplain. We maintain our Buy rating and our EUR10 PT.

07/30/25 July 30, 2025 1 EN
Free Trial
VLS VALNEVA SE

Valneva SE: 1 director

A director at Valneva SE bought 20,000 shares at 2.540EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

07/16/25 July 16, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva annonce la levée de la restriction temporaire de l'Agence euro...

Valneva annonce la levée de la restriction temporaire de l'Agence européenne des médicaments sur l'utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées Saint Herblain (France), le 11 juillet 2025 – (Nasdaq: VALN; Euronext Paris: VLA), (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) allait lever sa restriction temporaire sur la vaccination des personnes âgées de 65 et plus avec le vaccin à dose unique contre le chikungunya IXCHIQ® de Valneva suite à l’achèvement d’une ...

July 11, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Announces Lifting of European Medicines Agency’s Temporary Res...

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly Saint Herblain (France), July, 11 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC). The committee initiated its review at the beginning of May following the occurrence of serious sid...

July 11, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Declaration of shares and voting rights: June 30, 2025

VALNEVA Declaration of shares and voting rights: June 30, 2025 VALNEVA Declaration of shares and voting rights June 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: July 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voti...

July 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch